183 related articles for article (PubMed ID: 30671635)
1. Carcinoembryonic antigen reduction after medical treatment in patients with metastatic colorectal cancer: a systematic review and meta-analysis.
Colloca GA; Venturino A; Guarneri D
Int J Colorectal Dis; 2019 Apr; 34(4):657-666. PubMed ID: 30671635
[TBL] [Abstract][Full Text] [Related]
2. Clinical significance of changes in systemic inflammatory markers and carcinoembryonic antigen levels in predicting metastatic colorectal cancer prognosis and chemotherapy response.
Kim IH; Lee JE; Yang JH; Jeong JW; Ro S; Lee MA
Asia Pac J Clin Oncol; 2018 Jun; 14(3):239-246. PubMed ID: 29044941
[TBL] [Abstract][Full Text] [Related]
3. Relevance of baseline carcinoembryonic antigen for first-line treatment against metastatic colorectal cancer with FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial).
Holch JW; Ricard I; Stintzing S; Fischer von Weikersthal L; Decker T; Kiani A; Vehling-Kaiser U; Heintges T; Kahl C; Kullmann F; Scheithauer W; Moehler M; Jelas I; Modest DP; Westphalen CB; von Einem JC; Michl M; Heinemann V
Eur J Cancer; 2019 Jan; 106():115-125. PubMed ID: 30496943
[TBL] [Abstract][Full Text] [Related]
4. CEA Response and Depth of Response (DpR) to Predict Clinical Outcomes of First-Line Cetuximab Treatment for Metastatic Colorectal Cancer.
Sunakawa Y; Tsuji A; Denda T; Segawa Y; Negoro Y; Shimada K; Kochi M; Nakamura M; Kotaka M; Tanioka H; Takagane A; Tani S; Yamaguchi T; Watanabe T; Takeuchi M; Fujii M; Ichikawa W
Target Oncol; 2017 Dec; 12(6):787-794. PubMed ID: 29064002
[TBL] [Abstract][Full Text] [Related]
5. Clinical validity of tissue carcinoembryonic antigen expression as ancillary to serum carcinoembryonic antigen concentration in patients curatively resected for colorectal cancer.
Park JW; Chang HJ; Kim BC; Yeo HY; Kim DY
Colorectal Dis; 2013 Sep; 15(9):e503-11. PubMed ID: 23711333
[TBL] [Abstract][Full Text] [Related]
6. TIMP-1 and CEA as biomarkers in third-line treatment with irinotecan and cetuximab for metastatic colorectal cancer.
Spindler KL; Christensen IJ; Nielsen HJ; Jakobsen A; Brünner N
Tumour Biol; 2015 Jun; 36(6):4301-8. PubMed ID: 25608838
[TBL] [Abstract][Full Text] [Related]
7. Clinical Significance of Discordance between Carcinoembryonic Antigen Levels and RECIST in Metastatic Colorectal Cancer.
Kim IH; Lee JE; Yang JH; Jeong JW; Ro S; Oh ST; Kim JG; Choi MH; Lee MA
Cancer Res Treat; 2018 Jan; 50(1):283-292. PubMed ID: 28494536
[TBL] [Abstract][Full Text] [Related]
8. Carcinoembryonic Antigen-related Tumor Kinetics After Eight Weeks of Chemotherapy is Independently Associated With Overall Survival in Patients With Metastatic Colorectal Cancer.
Colloca GA; Venturino A; Guarneri D
Clin Colorectal Cancer; 2020 Dec; 19(4):e200-e207. PubMed ID: 32952072
[TBL] [Abstract][Full Text] [Related]
9. A retrospective cohort study of metastatic colorectal cancer patients treated with oxaliplatin-based chemotherapy, with an exploratory analysis of changing serum carcinoembryonic antigen levels.
Ng SL; Burns WI; Snyder RD; Newnham GM; McLachlan SA; Liew D; Dowling AJ
Asia Pac J Clin Oncol; 2012 Jun; 8(2):172-9. PubMed ID: 22524576
[TBL] [Abstract][Full Text] [Related]
10. Baseline carcinoembryonic antigen as a predictive factor of ramucirumab efficacy in RAISE, a second-line metastatic colorectal carcinoma phase III trial.
Yoshino T; Obermannová R; Bodoky G; Garcia-Carbonero R; Ciuleanu T; Portnoy DC; Kim TW; Hsu Y; Ferry D; Nasroulah F; Tabernero J
Eur J Cancer; 2017 Jun; 78():61-69. PubMed ID: 28412590
[TBL] [Abstract][Full Text] [Related]
11. Baseline and On-Treatment Markers Determining Prognosis of First-Line Chemotherapy in Combination with Bevacizumab in Patients with Metastatic Colorectal Cancer.
Quidde J; Denne L; Kutscheidt A; Kindler M; Kirsch A; Kripp M; Petersen V; Schulze M; Seraphin J; Tummes D; Arnold D; Stein A
Oncol Res Treat; 2017; 40(1-2):21-26. PubMed ID: 28192780
[TBL] [Abstract][Full Text] [Related]
12. Accessing new prognostic significance of preoperative carcinoembryonic antigen in colorectal cancer receiving tumor resection: More than positive and negative.
Cai Z; Xiao J; He X; Ke J; Zou Y; Chen Y; Wu X; Li X; Wang L; Wang J; Lan P; Wu X
Cancer Biomark; 2017; 19(2):161-168. PubMed ID: 28128739
[TBL] [Abstract][Full Text] [Related]
13. Threshold Change in CEA as a Predictor of Non-Progression to First-Line Systemic Therapy in Metastatic Colorectal Cancer Patients With Elevated CEA.
Gulhati P; Yin J; Pederson L; Schmoll HJ; Hoff P; Douillard JY; Hecht JR; Tournigand C; Tebbut N; Chibaudel B; Gramont A; Shi Q; Overman MJ
J Natl Cancer Inst; 2020 Nov; 112(11):1127-1136. PubMed ID: 32191317
[TBL] [Abstract][Full Text] [Related]
14. Is primary tumour resection associated with survival improvement in patients with colorectal cancer and unresectable synchronous metastases? A pooled analysis of individual data from four randomised trials.
Faron M; Pignon JP; Malka D; Bourredjem A; Douillard JY; Adenis A; Elias D; Bouché O; Ducreux M
Eur J Cancer; 2015 Jan; 51(2):166-76. PubMed ID: 25465185
[TBL] [Abstract][Full Text] [Related]
15. Prognostic role of neutrophil-to-lymphocyte ratio in colorectal cancer: a systematic review and meta-analysis.
Li MX; Liu XM; Zhang XF; Zhang JF; Wang WL; Zhu Y; Dong J; Cheng JW; Liu ZW; Ma L; Lv Y
Int J Cancer; 2014 May; 134(10):2403-13. PubMed ID: 24122750
[TBL] [Abstract][Full Text] [Related]
16. Concordance of Carcinoembryonic Antigen Ratio and Response Evaluation Criteria in Solid Tumors as Prognostic Surrogate Indicators of Metastatic Colorectal Cancer Patients Treated with Chemotherapy.
Huang SC; Lin JK; Lin TC; Chen WS; Yang SH; Wang HS; Lan YT; Lin CC; Jiang JK; Chang SC
Ann Surg Oncol; 2015 Jul; 22(7):2262-8. PubMed ID: 25586242
[TBL] [Abstract][Full Text] [Related]
17. CEA change after neoadjuvant chemotherapy including bevacizumab and clinical outcome in patients undergoing liver resection for colorectal liver metastases.
Stremitzer S; Stift J; Graf A; Singh J; Starlinger P; Gruenberger B; Tamandl D; Gruenberger T
Ann Surg Oncol; 2015 Apr; 22(4):1315-23. PubMed ID: 25323471
[TBL] [Abstract][Full Text] [Related]
18. Total cell-free DNA, carcinoembryonic antigen, and C-reactive protein for assessment of prognosis in patients with metastatic colorectal cancer.
Spindler KG; Demuth C; Sorensen BS; Johansen JS; Nielsen D; Pallisgaard N; Hoegdall E; Pfeiffer P; Vittrup Jensen B
Tumour Biol; 2018 Nov; 40(11):1010428318811207. PubMed ID: 30486767
[TBL] [Abstract][Full Text] [Related]
19. CEA increase as a marker of disease progression after first-line induction therapy in metastatic colorectal cancer patients. A pooled analysis of TRIBE and TRIBE2 studies.
Moretto R; Rossini D; Conca V; Lonardi S; Rasola C; Antoniotti C; Santini D; Marmorino F; Tomasello G; Borelli B; Caponnetto S; Zucchelli G; Zaniboni A; Ambrosini M; Buonadonna A; Fanchini L; Cupini S; Masi G; Falcone A; Cremolini C
Br J Cancer; 2021 Sep; 125(6):839-845. PubMed ID: 34253871
[TBL] [Abstract][Full Text] [Related]
20. The prognostic role of baseline CEA and CA 19-9 values and their time-dependent variations in advanced colorectal cancer patients submitted to first-line therapy.
Tampellini M; Ottone A; Alabiso I; Baratelli C; Forti L; Berruti A; Aroasio E; Scagliotti GV
Tumour Biol; 2015 Mar; 36(3):1519-27. PubMed ID: 25374062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
